The purpose of the present study was to evaluate the serum lipid lowering effect of gemfibrozil in long-term treatment.
Patients and Methods
A total of 34 subjects with primary hyperlipidemia were treated with gemfibrozil for six months or more. The subjects were considered to be hyperlipidcmic if they had either serum fasting levels of cholesterol above 7.75 mmol/l, triglycerides above 2.25 mmol/l, or both. The cohort comprised 19 males and 15 females. Ages varied from 19 years to 71 years, the mean being 51.5 years. Four patients had xanthomas, 2 had electrocardiographic evidence of myocardial infarction, 1 had left bundle branch block and 1 right bundle branch block. Two patients had a history of angina of effort.
In addition to serum lipids, physical examination and laboratory tests including ESR (Westergren), hTmoglobin, heematocrit, red and white cell counts, and serum GPT, urinalysis and ECG were performed to observe any side effects. Secondary hyperlipidmmias were excluded by clinical examination and the appropriate laboratory tests.
The subjects were first treated with placebo for four weeks. During this time serum lipids were determined three times (Days 1, 14 and 28), and the mean of these measurements was used as the non-treatment value.
After the placebo period, active treatment with gemfibrozil at 800 mg daily was begun, the daily dose being given in two equal portions. The control visits occurred at four-weekly intervals. During these visits samples were taken for monitoring serum lipids and GPT, ESR, haematocrit, white cell count and for doing a urinalysis. (7) Numbers of patients with a fall ofserum cholesterol below 7.75 mmol/l shown in parentheses
The subjects were weighed and enquiries were made about any adverse reactions. They were instructed to continue their normal day-to-day habits as far as possible, especially those relating to food intake, physical activity and smoking. If an adequate reduction in serum lipids was not evident after three months, the dose of gemfibrozil was progressively increased to a maximum daily dose of 1600 mg.
All laboratory determinations were carried out after overnight fasting. Serum triglycerides were determined by the Auto Analyzer method, cholesterol according to Pearson et al. (1953) . The method of Noble (1968) was modified for the determination of serum lipoproteins by agarose gel electrophoresis. Total lipids were determined according to Zollner & Kirsch (1962) . Boehringer reagent kits were used for the determination of serum GPT, alkaline phosphatase and CK.
The mean serum cholesterol concentration measured before the active treatment period was above 7.75 mmol/l in 31 subjects. Ten subjects had serum triglyceride levels above 2.25 mmol/l. The initial non-treatment cholesterol concentration varied between 7.8 and 12.9 mmol/l, the mean being 9.53 mmol/l. The non-treatment triglyceride values varied from 0.8 mmol/l to 11.2 mmol/l with a mean of 2.51 mmol/l. When classified according to Fredrickson types, 25 subjects belonged to type hIa, 2 to Ilb, 2 to 'floating III', and 2 to type IV.
Results
Serum cholesterol: After one month of treatment, the cholesterol level was decreased more than 10% in 21 subjects out of 31, and in 12 the serum cholesterol was below 7.75 mmol/l (Table 1) .
While one month of treatment showed a decreased trend in serum cholesterol, a more pronounced effect was seen after three months ( Fig  1) . From the values obtained at three months, it can be seen that there are patients who remained resistant, with a minimal change, if any, in serum cholesterol. The increase of the dose of gemfibrozil to 1200 mg after three months of treatment resulted in a more pronounced hypocholesterolemic effect (Fig 2) in most subjects. This hypolipidtmic action of gemfibrozil seems to be sustained (Fig 3) .
After six months of treatment, the serum cholesterol was below 7.75 mmol/l in 11 out of 31 subjects. In addition there were 8 subjects with a reduction of less than 10%. In 23 subjects the decrease was more than 10 %, in 8 of whom it was more than 21 % (Table 1) . After one year the serum cholesterol was below 7.75 mmol/l in 7 subjects out of 15. The reduction was more than 10% in 8, in 3 of whom it was more than 21 %, but in 7 it was less than 10%. Those 10 subjects had initial levels above 2.25 mmol/l. After treatment for one month the levels were decreased by more than 35 % in 8 subjects and 6 of them achieved normal levels. The effect was sustained for the next five months. In 8 subjects treated for one year, all but 3 showed a fall in serum triglycerides of more than 35% from the pretreatment values.
Lipoprotein electrophoresis: Lipoprotein electrophoresis was carried out in 11 type hIa subjects twice during the pretreatment period, and after six months' treatment with gemfibrozil (Table 2) . There was a clear reduction in the concentration of the beta-lipoprotein fraction in all subjects, and the mean value decreased from 6.93 g/l to 5.37 g/l. The pre-beta and alpha-lipoprotein fractions remained virtually unchanged throughout the trial. respond belonged to type IIa and most had a family history of hypercholesterolemia. Reduction in serum cholesterol values in a family consisting of mother (51 years), daughter (20 years) and son (19 years) is shown in Fig 4. The respective initial pretreatment values were 12.9 mmol/l, 10.9 mmol/l and 10.6 mmol/l. It can be seen that the cholesterol was initially decreased in all of them. During the course of the trial, however, only the 20-year-old daughter maintained a low level of serum cholesterol. The role played by sex and age in the response of the individual family members needs further investigation.
Serum triglycerides: The fall of serum triglyceride levels during treatment with gemfibrozil was clearer than that of cholesterol ( Fig 5) . Concentrations were normal even in the nontreatment period, and so reductions were not necessarily desirable in their case. Most of the fall in the triglyceride levels in these type Ila subjects seems to have been associated with the decreased beta-lipoprotein, as was the fall in the serum cholesterol level.
Tolerance: Gemfibrozil was well tolerated in all subjects participating in the trial. None dropped out because of the drug. Neither serum GPT, hematology nor urinalysis indicated any evidence of side effects or organ toxicity. The subjects were free from subjective side effects associated with the drug; this was also evident from the fact that all wished to continue the trial.
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Conclusions
The results of this long-term trial warrant consideration of gemfibrozil as an effective lipid lowering agent. The failure of some patients to respond does not weaken the claim. From the practical point of view, the classification of hyperlipidemias into different subtypes has contributed to the understanding of their pathogenesis. However, much remains unresolved. In the practical situation of treating patients, the value of this precise classification, cumbersome and not always completely accurate as it is, has been questioned, even by Fredrickson (1972) . The reason is that the efficacy of an agent cannot be predicted for all patients even when there is a tendency for certain hypolipidcemic agents to be more effective in certain types of hyperlipidamias. We lack the knowledge of the pathogenesis of the hyperlipidaemias and the mode of action of the lipid lowering agents. There can be no certainty in any case about the complete effectiveness of a drug, until it has been tried.
The treatment of hyperlipidcmia is often tailor-made to the individual. Experience is of great value in finding the most suitable agent. Long-term trials of an agent with a variety of subjects are also very necessary. The lipid lowering effect of gemfibrozil seems to be more pronounced for triglycerides than for cholesterol. However, both cholesterol and the beta-lipoproteins are decreased, indicating that not only subjects with high triglycerides and pre-beta lipoproteins, but also those with high cholesterol and beta-lipoproteins may benefit from the hypolipidxmic action of gemfibrozil. From the practical point of view, gemfibrozil has two very important characteristics in the treatment of hyperlipidamias: it is free of side effects and its effect is sustained.
